ClinicalTrials.gg
Not yet recruitingNCT07666087Updated Jun 24, 2026

Pilot Usability Study to Set Up and Use the Feetsee™ Foot Monitoring Device in Adults With Diabetes

An observational study in Diabetes, sponsored by Diabetis JSC. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Diabetis JSC · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,023 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 388 under way, 12 of them phase 3. Diabetes Mellitus · United States.

Planned enrollment
435th of 499
20 · median 159
Started
2026
with 95 others
Observational
507 of 3,023
76 open now
Primary completion
2027-05
later than 173 of 380 live
Registered
2,993rd of 3,023
by date

Among the 3,023 studies in Diabetes Mellitus with a site in United States, this one is the 435th largest by planned enrollment of the 499 observational ones that give a count, is one of 96 that started in 2026, is one of 507 observational ones, reaches primary completion later than 173 of the 380 other live ones, and was the 2,993rd registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

289 of the 3,023 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:

284 more — sign in →

All 289 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,023 studies in Diabetes Mellitus with a site in United States, or all of them as a file.
02

Study summary

Single-center, prospective, minimal-risk, non-experimental usability study assessing the setup and use of the FDA-registered (Class I medical device; 510(k)-exempt) Feetsee™ home foot-monitoring system by adults with diabetes in their home environment over 8 weeks.

This study in non clinical, observational pilot usability study conducted under FDA Human Factors and Usability Engineering guidance (2016).

Read the detailed description

Participants will be recruited from outpatient diabetes and podiatry clinics at UT Health San Antonio, an academic medical center. The study itself is conducted as a home-use usability study: after initial training, participants set up and use the Feetsee foot-monitoring system in their own homes, following the US IFU and in-app instructions. Data will be collected via paper/electronic CRFs, patient questionnaires, and Feetsee device/app usage logs (exported to REDCap and secure sponsor databases).

03

Conditions studied

  • Diabetes

Browse trials for

Keywords

  • Foot monitoring
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will enroll adult participants with diabetes who are at risk for diabetic foot complications and who are able to use a smartphone-based home monitoring system. Participants represent the intended user population of the Feetsee™ Foot Monitoring System.

Participants will be recruited from diabetes, endocrinology, and podiatry clinics at UT Health San Antonio and affiliated University Health clinical sites under the supervision of the Principal Investigator.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females aged 18 years or older
  • Clinical diagnosis of Type 1 or Type 2 diabetes
  • At least one palpable foot pulse per feet
  • Possess basic ability to use a smartphone or tablet
  • Have no prior experience with the Feetsee™ system
  • Be willing and able to provide

Exclusion criteria

Exclusion Criteria:

  • Active foot ulceration at enrollment
  • Active Charcot neuro-osteoarthropathy
  • Severe vascular disease (complete absence of foot pulses)
  • Amputation of more than three toes
  • Active or condition
  • Cognitive or physical impairments preventing proper device usage
  • Concurrent participation in another study with procedures
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Type 1 or Type 2 diabetes, recruited from outpatient clinics

    Approximately 20 adults (≥18 years) with Type 1 or Type 2 diabetes, recruited from outpatient clinics at UT Health San Antonio

    Device: Pilot Usability Study to Set Up and Use the Feetsee™ Foot Monitoring Device

Interventions

  • DevicePilot Usability Study to Set Up and Use the Feetsee™ Foot Monitoring Device

    : after initial training, participants set up and use the Feetsee foot-monitoring system in their own homes, following the US IFU and in-app instructions. Data will be collected via paper/electronic CRFs, patient questionnaires, and Feetsee device/app usage logs (exported to REDCap and secure sponsor databases).

06

What researchers measure

Primary outcomes

  1. Usability of the Feetsee Foot Monitoring System

    • To evaluate the usability of the Feetsee Foot Monitoring System by both patients and healthcare providers when they use only the provided labeling, Quick Start Guide, Instructions for Use (IFU), and in-app instructions

    Time frame: 8 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for May 2027, 10 months later.

Of 109 industry-sponsored observational studies under Diabetes Mellitus, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 39. This study's planned 10 months is below that.

Counting every sponsor, half of 643 studies reached it within 36 months; a quarter within 14 and three quarters within 122.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 24, 2026
StartEst.
Jul 10, 2026
Primary completionEst.
May 27, 2027
CompletionEst.
Jul 10, 2027
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07666087
Lead sponsor
Diabetis JSC
Responsible party
Sponsor
First posted
Jun 24, 2026
Start date
Jul 10, 2026 (estimated)
Primary completion
May 27, 2027 (estimated)
Completion
Jul 10, 2027 (estimated)
Last update
Jun 24, 2026

Study contacts

Helena Grinberg, PhD
Contact
lenagrin@gmail.com
+31615636666
Rytis Zajančkauskas, MD
Contact
rytis@diabetis.lt
Lawrence A. Lavery, MD
principal investigator · The University of Texas Health Science Center at San Antonio

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion